Compare with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES AJANTA PHARMA ALKEM LABORATORIES/
AJANTA PHARMA
 
P/E (TTM) x 24.4 27.3 89.4% View Chart
P/BV x 5.9 6.7 87.3% View Chart
Dividend Yield % 0.8 0.5 157.6%  

Financials

 ALKEM LABORATORIES   AJANTA PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
AJANTA PHARMA
Mar-19
ALKEM LABORATORIES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs2,7201,422 191.3%   
Low Rs1,660898 185.0%   
Sales per share (Unadj.) Rs697.9233.5 298.9%  
Earnings per share (Unadj.) Rs96.144.0 218.6%  
Cash flow per share (Unadj.) Rs117.352.2 224.8%  
Dividends per share (Unadj.) Rs25.009.00 277.8%  
Dividend yield (eoy) %1.10.8 147.1%  
Book value per share (Unadj.) Rs515.2255.1 202.0%  
Shares outstanding (eoy) m119.5788.02 135.8%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.15.0 63.2%   
Avg P/E ratio x22.826.4 86.4%  
P/CF ratio (eoy) x18.722.2 84.0%  
Price / Book Value ratio x4.34.5 93.5%  
Dividend payout %26.020.5 127.1%   
Avg Mkt Cap Rs m261,879102,081 256.5%   
No. of employees `00014.36.8 210.8%   
Total wages/salary Rs m15,0554,307 349.5%   
Avg. sales/employee Rs Th5,822.63,022.6 192.6%   
Avg. wages/employee Rs Th1,050.5633.4 165.9%   
Avg. net profit/employee Rs Th802.0569.1 140.9%   
INCOME DATA
Net Sales Rs m83,44420,554 406.0%  
Other income Rs m1,042211 494.4%   
Total revenues Rs m84,48620,765 406.9%   
Gross profit Rs m14,7345,664 260.1%  
Depreciation Rs m2,528721 350.7%   
Interest Rs m65112 5,608.6%   
Profit before tax Rs m12,5985,143 245.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,1051,273 86.8%   
Profit after tax Rs m11,4933,870 297.0%  
Gross profit margin %17.727.6 64.1%  
Effective tax rate %8.824.8 35.4%   
Net profit margin %13.818.8 73.2%  
BALANCE SHEET DATA
Current assets Rs m54,96011,812 465.3%   
Current liabilities Rs m32,4333,776 858.8%   
Net working cap to sales %27.039.1 69.1%  
Current ratio x1.73.1 54.2%  
Inventory Days Days8077 102.8%  
Debtors Days Days7282 88.4%  
Net fixed assets Rs m32,71014,398 227.2%   
Share capital Rs m239175 136.3%   
"Free" reserves Rs m61,36822,277 275.5%   
Net worth Rs m61,60722,452 274.4%   
Long term debt Rs m1,5927 24,127.3%   
Total assets Rs m99,43326,962 368.8%  
Interest coverage x20.4444.3 4.6%   
Debt to equity ratio x00 8,793.0%  
Sales to assets ratio x0.80.8 110.1%   
Return on assets %12.214.4 84.8%  
Return on equity %18.717.2 108.2%  
Return on capital %21.023.0 91.3%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,06110,682 150.4%   
Fx outflow Rs m2,4832,102 118.1%   
Net fx Rs m13,5788,580 158.3%   
CASH FLOW
From Operations Rs m5,8513,748 156.1%  
From Investments Rs m-7,414-2,228 332.7%  
From Financial Activity Rs m792-1,475 -53.7%  
Net Cashflow Rs m-73145 -1,617.5%  

Share Holding

Indian Promoters % 66.9 73.8 90.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 1.6 2,135.5%  
FIIs % 0.0 7.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 17.0 -  
Shareholders   68,381 20,968 326.1%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   J.B.CHEMICALS  SUVEN LIFE SCIENCES  WYETH  CADILA HEALTHCARE  VENUS REMEDIES  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Crucial Week Ahead for the Indian Stock Market(Momentum Moves)

The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 60.8% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 22, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS